<DOC>
	<DOCNO>NCT01964235</DOCNO>
	<brief_summary>This study establish whether INC280 safe beneficial effect patient advance hepatocellular carcinoma know dysregulation c-MET pathway whose disease progress , , treatment sorafenib intolerant sorafenib . Patients randomize 2:1 ratio receive INC280 600mg BID plus best supportive care ( BSC ) placebo plus BSC , disease progression intolerable study treatment . Patients treat placebo plus BSC opportunity receive INC280 treatment upon documented disease progression ( RECIST 1.1 ) per investigator 's discretion unblinding . Patient stratify geographical region ( Asia vs Rest World ) tumor burden ( present macroscopic vascular invasion and/or extra-hepatic spread v present ) .</brief_summary>
	<brief_title>Study Efficacy Safety INC280 Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Study cancel Sponsor prior enrollment patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed cMET pathway dysregulation . Hepatocellular carcinoma stage B C accord Barcelona Clinic Liver cancer stag classification . Current cirrhotic status ChildPugh class A encephalopathy . Documented disease progression discontinuation sorafenib treatment intolerance sorafenib treatment . Measurable disease determine RECIST v1.1 . ECOG performance status ≤ 1 Previous local antineoplastic therapy investigational drug complete less 5 halflives agent prior randomization recover clinically significant toxicity treatment grade ≤1 NCICTCAE . Received target therapy sorafenib . Active bleeding within 28 day prior screen visit include variceal bleeding ( esophageal varix treat accord standard practice procedure complete 28 day prior screen visit ) . Clinically significant venous arterial thrombotic disease within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>INC280 , advance hepatocellular carcinoma , c-MET pathway dysregulation .</keyword>
</DOC>